# Study: Abortion bans limit miscarriage treatment options for patients  
**Published:** 2026-05-18T21:48:04.000Z  
**Source:** [Nebraska Examiner](https://nebraskaexaminer.com/2026/05/18/repub/miscarriage-patients-have-fewer-treatment-options-in-states-with-abortion-bans-study-shows/)  
**AI-generated:** yes (claude-haiku-4-5-20251001)  
**Canonical:** https://lincolne.news/article/study-abortion-bans-limit-miscarriage-treatment-options-for-patients

A new study published in the Journal of the American Medical Association shows that pregnant patients experiencing miscarriage in states with abortion bans have fewer healthcare management options, according to reporting by the [Nebraska Examiner](https://nebraskaexaminer.com/2026/05/18/repub/miscarriage-patients-have-fewer-treatment-options-in-states-with-abortion-bans-study-shows/).

Researchers from Oregon Health and Science University found a significant shift away from the most effective two-drug approach to treating early pregnancy loss. The combination of mifepristone and misoprostol has been the recommended standard by the American College of Obstetricians and Gynecologists, but in states with abortion bans, doctors increasingly rely on misoprostol alone, which is less effective.

The study analyzed nearly 123,600 commercially insured patients who had a miscarriage before 77 days' gestation between 2018 and September 2024, comparing treatment patterns before and after the U.S. Supreme Court's 2022 Dobbs decision that allowed states to restrict abortion access. States with bans affecting pregnancies at six weeks or earlier showed a nearly 14% increase in misoprostol-only treatment and a 3% increase in expectant management, where doctors monitor the condition without prescribing treatment.

Expectant management can increase the risk of hemorrhage and retained pregnancy tissue, which may cause infection. When used together, the two medications are most effective at completing expulsion of tissue and reducing side effects such as bleeding and cramping.

The same two-drug combination is used to terminate pregnancy, which has created legal uncertainty for physicians treating miscarriage in abortion-restricted states. Louisiana classified both medications as controlled substances in 2024, and Mississippi added them to its drug trafficking law in April, making distribution punishable by up to 10 years in prison.

[Nebraska banned abortion after 12 weeks of pregnancy](https://reproductiverights.org/maps/state/nebraska/), with exceptions for medical emergencies and pregnancies resulting from sexual assault or incest. The state's restrictions have raised questions among medical providers about treatment options for miscarriage care, though state officials have maintained that exceptions exist for medical management of pregnancy loss.

## Sources

- [Nebraska Examiner](https://nebraskaexaminer.com/2026/05/18/repub/miscarriage-patients-have-fewer-treatment-options-in-states-with-abortion-bans-study-shows/)
- [Center for Reproductive Rights information on Nebraska abortion law](https://reproductiverights.org/maps/state/nebraska/)
- [JAMA study on impact of abortion bans on miscarriage treatment](https://jamanetwork.com/journals/jama/fullarticle/2849131?resultclick=1)

---

This article was generated by AI (claude-haiku-4-5-20251001) based on source material from Nebraska Examiner, enriched with 2 web searches. The original source is available at https://nebraskaexaminer.com/2026/05/18/repub/miscarriage-patients-have-fewer-treatment-options-in-states-with-abortion-bans-study-shows/.